Comparison between Mahamaya Lifesciences IPO and Western Overseas Study Abroad IPO.
Mahamaya Lifesciences IPO is a SME Fixed Price IPO proposed to list at BSE SME while Western Overseas Study Abroad IPO is a SME Fixed Price proposed to list at BSE SME.
| Mahamaya Lifesciences IPO | Western Overseas Study Abroad IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Fixed Price |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Oneview Corporate Advisors Pvt.Ltd. | Sobhagya Capital Options Pvt.Ltd. |
| Registrar | Kfin Technologies Ltd. | Skyline Financial Services Pvt.Ltd. |
| Market Maker | Mansi Share & Stock Broking Pvt.Ltd. | Giriraj Stock Broking Pvt.Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Mahamaya Lifesciences IPO is up to ₹66.91 Cr whereas the issue size of the Western Overseas Study Abroad IPO is up to ₹9.56 Cr. The final issue price of Mahamaya Lifesciences IPO is ₹114.00 per share and of Western Overseas Study Abroad IPO is ₹56.00 per share.
| Mahamaya Lifesciences IPO | Western Overseas Study Abroad IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹108.00 per share | |
| Issue Price (Upper) | ₹114.00 per share | |
| Issue Price (Final) | ₹114.00 per share | ₹56.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1200 shares | 2000 shares |
| Fresh Issue Size | 53,29,200 shares | 17,08,000 shares |
| Fresh Issue Size (Amount) | up to ₹60.75 Cr | up to ₹9.56 Cr |
| OFS Issue Size | 5,40,000 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹6.16 Cr | up to ₹0.00 Cr |
| Issue Size Total | 58,69,200 shares | 17,08,000 shares |
| Issue Size Total (Amount) | up to ₹66.91 Cr | up to ₹9.56 Cr |
Mahamaya Lifesciences IPO opens on Nov 11, 2025, while Western Overseas Study Abroad IPO opens on Dec 04, 2025. The closing date of Mahamaya Lifesciences IPO and Western Overseas Study Abroad IPO is Nov 13, 2025, and Dec 08, 2025, respectively.
| Mahamaya Lifesciences IPO | Western Overseas Study Abroad IPO | |
|---|---|---|
| Anchor Bid Date | Nov 10, 2025 | |
| Issue Open | Nov 11, 2025 | Dec 04, 2025 |
| Issue Close | Nov 13, 2025 | Dec 08, 2025 |
| Basis Of Allotment (Tentative) | Nov 14, 2025 | Dec 09, 2025 |
| Initiation of Refunds (Tentative) | Nov 17, 2025 | Dec 10, 2025 |
| Credit of Share (Tentative) | Nov 17, 2025 | Dec 10, 2025 |
| Listing date (Tentative) | Nov 18, 2025 | Dec 11, 2025 |
| Anchor Lockin End date 1 | Dec 13, 2025 | |
| Anchor Lockin End date 2 | Feb 11, 2026 |
Mahamaya Lifesciences IPO P/E ratio is 15.65, as compared to Western Overseas Study Abroad IPO P/E ratio of 10.67.
| Mahamaya Lifesciences IPO | Western Overseas Study Abroad IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Mahamaya Lifesciences Ltd.'s revenue increased by 64% and profit after tax (PAT) rose by 148% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)Western Overseas Study Abroad Ltd.'s revenue increased by 13% and profit after tax (PAT) rose by 86% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 77.27 | 100 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 56.35 | 70.09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 15.65 | 10.67 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹266.82 Cr. | ₹33.67 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 34.94% | 40.18% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 23.15% | 37.63% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.08 | 0.63 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹7.29 | ₹5.25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 26.19% | 33.86% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Mahamaya Lifesciences IPO Retail Individual Investors (RII) are offered 20,59,200 shares while in Western Overseas Study Abroad IPO retail investors are offered 20,59,200 shares. Qualified Institutional Buyers (QIB) are offered 11,76,000 shares in Mahamaya Lifesciences IPO and 0 shares in Western Overseas Study Abroad IPO.
| Mahamaya Lifesciences IPO | Western Overseas Study Abroad IPO | |
|---|---|---|
| Anchor Investor Reservation | 17,52,000 shares | 0 shares |
| Market Maker Reservation | 3,09,600 shares | 90,000 shares |
| QIB | 11,76,000 shares | 0 shares |
| NII | 8,82,000 shares | 8,54,000 shares |
| RII | 20,59,200 shares | 8,54,000 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 58,69,200 shares | 17,08,000 shares |
Mahamaya Lifesciences IPO subscribed 1.63x in total, whereas Western Overseas Study Abroad IPO subscribed 1.41x.
| Mahamaya Lifesciences IPO | Western Overseas Study Abroad IPO | |
|---|---|---|
| QIB (times) | 1.19x | |
| NII (times) | 3.63x | 0.39x |
| Big NII (times) | 5.00x | |
| Small NII (times) | 0.90x | |
| RII (times) | 1.02x | 2.43x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 1.63x | 1.41x |
